Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Assertio Therapeutics, Inc (ASRT)
|
Add to portfolio |
|
|
|
| Price: |
$0.81
| | Metrics |
| OS: |
81.4
|
M
| |
-192
|
% ROE
|
| Market cap: |
$65.7
|
M
| |
|
|
|
Net cash:
|
$114
|
M
| |
$1.40
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$64.6
|
M
| |
-0.7
|
x EV/EBITDA
|
|
EBIT
|
($20.5)
|
M
| |
|
|
| EPS |
($2.31)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 229.5 | 311.8 | 380.7 | 455.9 | 342.7 | 390.4 | 134.2 | 90.8 |
| Revenue growth | -26.4% | -18.1% | -16.5% | 33.0% | -12.2% | 190.9% | 47.8% | -31.7% |
| Cost of goods sold | 9.5 | 18.5 | 72.6 | 87.4 | 67.9 | 15.1 | 7.1 | 6.0 |
| Gross profit | 220.0 | 293.3 | 308.1 | 368.5 | 274.8 | 375.2 | 127.1 | 84.8 |
| Gross margin | 95.9% | 94.1% | 80.9% | 80.8% | 80.2% | 96.1% | 94.7% | 93.4% |
| Selling, general and administrative | 108.9 | 119.2 | 195.7 | 204.5 | 199.4 | 121.1 | 105.2 | 97.6 |
| Research and development | 10.1 | 8.0 | 13.7 | 32.6 | 17.5 | 7.1 | 8.1 | 15.5 |
| EBITA | 101.0 | 228.0 | 115.8 | 131.4 | 57.9 | 247.0 | 13.9 | -28.3 |
| EBITA margin | 44.0% | 73.1% | 30.4% | 28.8% | 16.9% | 63.3% | 10.3% | -31.2% |
| Amortization of intangibles | 101.8 | 101.8 | 102.7 | 106.8 | 83.3 | 10.2 | 4.5 | 2.0 |
| EBIT | -0.7 | 126.3 | 13.0 | 24.5 | -25.4 | 236.8 | 9.3 | -30.4 |
| EBIT margin | -0.3% | 40.5% | 3.4% | 5.4% | -7.4% | 60.7% | 6.9% | -33.4% |
| Pre-tax income | -222.5 | 38.0 | -103.9 | -64.5 | -123.2 | 213.1 | 4.6 | -29.9 |
| Income taxes | -5.3 | 1.1 | -1.4 | 24.2 | -47.5 | 81.3 | -38.7 | -0.1 |
| Tax rate | 2.4% | 2.8% | 1.4% | | 38.5% | 38.2% | | 0.3% |
| Net income | -217.2 | 36.9 | -102.5 | -88.7 | -75.7 | 131.8 | 43.3 | -29.8 |
| Net margin | -94.6% | 11.8% | -26.9% | -19.5% | -22.1% | 33.8% | 32.3% | -32.8% |
| |
| Diluted EPS | ($3.07) | $0.57 | ($1.63) | ($1.45) | ($1.26) | $1.99 | $0.75 | ($0.53) |
| Shares outstanding (diluted) | 70.7 | 64.2 | 62.7 | 61.3 | 60.1 | 66.3 | 57.5 | 55.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|